腹腔热灌注化疗联合静脉化疗在肿瘤细胞减灭术后晚期卵巢癌患者中的应用效果

Application effects of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in patients with advanced ovarian cancer after cytoreductive surgery

目的:观察腹腔热灌注化疗联合静脉化疗在肿瘤细胞减灭术后晚期卵巢癌患者中的应用效果。方法:选取65例行CRS后的晚期卵巢癌患者作为研究对象,按随机数字表法分为观察组33例和对照组32例。对照组给予紫杉醇联合顺铂静脉化疗,观察组在对照组的基础上联合腹腔热灌注化疗,比较两组临床疗效,治疗前后血清糖类抗原125(CA125)水平,腹水控制率和不良反应发生率,以及随访1年的复发率。结果:观察组治疗总有效率为84.85%,高于对照组的62.50%,差异有统计学意义(P<0.05);治疗后,观察组血清CA125水平低于对照组,腹水控制率高于对照组,差异均有统计学意义(P<0.05);观察组复发率为18.18%,低于对照组的43.75%,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:腹腔热灌注化疗联合静脉化疗应用于CRS术后晚期卵巢癌患者,可提高腹水控制率,降低血清CA125水平和复发率,其效果优于单纯静脉化疗。

Objective:To observe application effects of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in patients with advanced ovarian cancer after cytoreductive surgery(CRS).Methods:65 patients with advanced ovarian cancer who underwent CRS were selected as the research objects,and were divided into observation group(33 cases)and control group(32 cases)according to the random number table method.The control group was given Paclitaxel combined with Cisplatin intravenous chemotherapy,while the observation group was combined with hyperthermic intraperitoneal chemotherapy on the basis of that of the control group.The clinical efficacy,the serum carbohydrate antigen 125(CA125)levels before and after the treatment,the ascites control rate,the incidence of adverse reactions,and the recurrence rate at 1-year follow-up were compared between the two groups.Results:The total effective rate of treatment in the observation group was 84.85%,which was higher than 62.50%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the serum CA125 level of the observation group was lower than that of the control group;the ascites control rate was higher than that of the control group;and the differences were statistically significant(P<0.05).The recurrence rate of the observation group was 18.18%,which was lower than the control group of 43.75%,and the difference was statistically significant(P<0.05).However,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in the treatment of the patients with advanced ovarian cancer after CRS can improve the ascites control rate and reduce the serum CA125 level and recurrence rate.Moreover,it is superior to simple intravenous chemotherapy.